Status:

UNKNOWN

Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis

Lead Sponsor:

Meluha Life Sciences SDN BHD

Conditions:

Osteoarthritis, Knee

Eligibility:

All Genders

30-70 years

Phase:

PHASE2

Brief Summary

Primary osteoarthritis is a debilitating disease characterized by extensive damage to the joints and excruciating pain leading to loss of activity and depression. Despite advances in diagnosis, the qu...

Detailed Description

Osteoarthritis is one of the commonest diseases in the world, with a global disease burden of 83%. Plain radiograph remained the main modality in diagnosing osteoarthritis. Chondrogen is a mesenchymal...

Eligibility Criteria

Inclusion

  • 30-70 years old
  • No serious infection, chronic diseases, diabetes and tuberculosis
  • Idiopathic or secondary osteoarthritis of the knee with grade 1-3 defined by the modified Kellgren-lawrence classification
  • Written informed consents were obtained from all subjects.

Exclusion

  • Pregnant or lactating women
  • Women of childbearing potential unwilling to use two forms of contraception
  • Cognitively impaired adults
  • Presence of large meniscal tears
  • Inflammatory or post-infectious arthritis
  • More than 5 degrees of varus or valgus deformity
  • Kellgren Lawrence grade 4 osteoarthritis in two compartments in persons over 60 years of age
  • Intra-articular corticosteroid injection within the 3 previous months
  • Major neurologic deficit
  • Arthroscopy during the previous 6 months
  • Poorly controlled diabetes mellitus
  • Immunosuppressive or anticoagulant treatment
  • NSAID therapy within 15 days prior to inclusion in the study
  • Serious medical illness with a life expectancy of less than 1 year
  • Prior admission for substance abuse
  • Body Mass Index (BMI) of 40 kg/m2 or greater
  • Patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent

Key Trial Info

Start Date :

October 31 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2022

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04520945

Start Date

October 31 2020

End Date

September 30 2022

Last Update

August 20 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Orthopedic & Traumatology, Faculty of Medicine, Hospital Canselor Tuanku Mukhriz, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur.

Cheras, Kuala Lumpur, Malaysia, 56000